Introduction – Company Background
GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.
With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.
With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.
From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.
At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.
By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.
Core Strengths in Insole Manufacturing
At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.
Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.
We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.
With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.
Customization & OEM/ODM Flexibility
GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.
Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.
With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.
Quality Assurance & Certifications
Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.
We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.
Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.
ESG-Oriented Sustainable Production
At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.
To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.
We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.
Let’s Build Your Next Insole Success Together
Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.
From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.
Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.
🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw
Custom graphene foam processing China
Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.
With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Vietnam graphene material ODM solution
Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.
We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Taiwan graphene product OEM service
At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Thailand orthopedic insole OEM manufacturer
📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Graphene-infused pillow ODM China
Compared with a normal cell (left), an oligodendrocyte lacking TDP-43 (center) produces less myelin (green) because it is unable to synthesize or take up sufficient amounts of cholesterol. Supplementing TDP-43–deficient cells with cholesterol (right) restores myelin production. Credit: ©2021 Ho et al. Originally published in Journal of Cell Biology. https://doi.org/10.1083/jcb.201910213 Researchers in Singapore have discovered that brain cells cannot maintain the cholesterol-rich myelin sheath that protects and insulates neurons in the absence of a protein called TDP-43. The study, which will be published today (August 4, 2021) in the Journal of Cell Biology (JCB), suggests that restoring cholesterol levels could be a new therapeutic approach for diseases associated with TDP-43. The TDP-43 protein is linked to multiple neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 plays many vital roles within cells, but, under certain circumstances, it can clump together to form toxic aggregates that damage cells and prevent TDP-43 from performing its normal functions. TDP-43 aggregates are found in the brains of most ALS patients and ~45% of FTD patients and are also linked to several other neurodegenerative disorders, including some cases of Alzheimer’s disease. The aggregates form not only in neurons, but also in other brain cell types such as oligodendrocytes. These latter cells protect neurons and speed up the transmission of nerve impulses by wrapping neurons in a fatty substance called myelin. Shuo-Chien Ling and colleagues at the Yong Loo Lin School of Medicine, National University of Singapore, have previously shown that oligodendrocytes need TDP-43 to survive and wrap neurons in myelin. “Specifically, we found that mice with oligodendrocytes lacking TDP-43 develop progressive neurological phenotypes leading to early lethality. These phenotypes were accompanied by the death of oligodendrocytes and progressive loss of myelin,” Ling says. In the new study, Ling and colleagues find that one reason oligodendrocytes are dysfunctional in the absence of TDP-43 is that they are unable to synthesize or take up the cholesterol they need to sustain myelin production. Cholesterol is such a major component of myelin that 25% of the body’s total cholesterol can be found in the central nervous system. Oligodendrocytes are known to synthesize large amounts of cholesterol for themselves, but they can also acquire it from other brain cells called astrocytes. Ling and colleagues determined that, in the absence of TDP-43, oligodendrocytes lack many of the enzymes required to synthesize cholesterol, and also have reduced levels of the low density lipoprotein receptor that can take in cholesterol from outside the cell. Supplementing these TDP-43–deficient cells with cholesterol restored their ability to maintain the myelin sheath. Similar defects in cholesterol metabolism may occur in patients, where the formation of aggregates might prevent TDP-43 from performing its normal functions. Ling and colleagues analyzed brain samples from FTD patients and found that their oligodendrocytes produced lower amounts of two key enzymes required for cholesterol synthesis, while the low density lipoprotein receptor was incorporated into TDP-43 aggregates. “Our results indicate that simultaneous disruption of cholesterol synthesis and uptake is likely one of the causes of the demyelination phenotype observed in mice with TDP-43–deficient oligodendrocytes, and suggest that defects in cholesterol metabolism may contribute to ALS and FTD, as well as other neurodegenerative diseases characterized by TDP-43 aggregates,” Ling says. Drugs that modulate cholesterol metabolism might therefore be a novel therapeutic strategy to treat these diseases, the researchers suggest. Reference: “TDP-43 mediates SREBF2-regulated gene expression required for oligodendrocyte myelination” by Wan Yun Ho, Jer-Cherng Chang, Kenneth Lim, Amaury Cazenave-Gassiot, Aivi T. Nguyen, Juat Chin Foo, Sneha Muralidharan, Ashley Viera-Ortiz, Sarah J.M. Ong, Jin Hui Hor, Ira Agrawal, Shawn Hoon, Olubankole Aladesuyi Arogundade, Maria J. Rodriguez, Su Min Lim, Seung Hyun Kim, John Ravits, Shi-Yan Ng, Markus R. Wenk, Edward B. Lee, Greg Tucker-Kellogg and Shuo-Chien Ling, 4 August 2021, Journal of Cell Biology. DOI: 10.1083/jcb.201910213
Researchers have identified BbLDH as a critical enzyme for B. burgdorferi survival, paving the way for targeted Lyme disease treatments. New inhibitors could halt the bacteria without affecting other organisms, making this a major step forward. A team of scientists has zeroed in on an enzyme that could revolutionize Lyme disease treatment. By uncovering the crucial role of BbLDH in bacterial survival and infectivity, they’ve opened the door to highly targeted therapeutics. Their findings even hint at broader applications for fighting other tick-borne diseases. A Promising New Target for Lyme Disease Treatment Scientists have identified an enzyme that could be a promising target for developing new treatments for Lyme disease, and potentially other tick-borne illnesses. Their findings, published today (March 20) in mBio, a journal of the American Society for Microbiology, could open the door to more effective therapies. Lyme disease is the most common tick-borne infection in the United States and Europe. It is caused by the bacterium Borrelia burgdorferi, which has evolved unique metabolic pathways to survive in its environment. Some of these pathways make ideal targets for drug development. A Surprising Metabolic Pathway Previous research from Virginia Commonwealth University revealed that B. burgdorferi does not rely on thiamin, an essential cofactor for most organisms. Instead, it depends on the enzyme lactate dehydrogenase (BbLDH) to convert pyruvate to lactate, a process crucial for maintaining its NADH/NAD+ balance. This metabolic adaptation has not been observed in any other microorganism and plays a vital role in the bacterium’s survival. In this new study, researchers explored the function of BbLDH in B. burgdorferi and its potential as a therapeutic target. Using genetic, biochemical, and structural analysis, including X-ray crystallography, they identified BbLDH’s essential role in the bacterium’s growth and ability to infect a host. Loss-of-function studies confirmed that BbLDH is necessary for the bacterium to thrive both in lab cultures and in living organisms. Additionally, the team performed high-throughput screening and discovered several promising LDH inhibitors that could serve as the basis for future treatments. A Breakthrough in Lyme Disease Therapeutics “We discovered that BbLDH has a unique biochemical and structural feature and it is essential for B. burgdorferi growth and infectivity,” said corresponding study author Chunhao (Chris) Li, M.S., M.D., Edward Myers Endowed Professor, the Philips Research Institute for Oral Health, School of Dentistry, Virginia Commonwealth University. “BbLDH can serve as an ideal target for developing genus-specific inhibitors that can be potentially used to treat and prevent Lyme disease.” The impact of Lyme disease on public health fuels an emerging demand for novel therapeutics to treat Lyme disease. “This report also sheds new light into understanding the role of LDH in the pathophysiology of other tick-borne pathogens,” Li said. Reference: “Lactate dehydrogenase is the Achilles’ heel of Lyme disease bacterium Borreliella burgdorferi” by Ching Wooen Sze, Michael J. Lynch, Kai Zhang, David B. Neau, Steven E. Ealick, Brian R. Crane and Chunhao Li, 20 March 2025, mBio. DOI: 10.1128/mbio.03728-24
Left: Heba Shabaan, a third-year medical student at Weill Cornell Medical College and Dr. Christopher Mason prepare to swab for microbes in the NYC subway system on June 21, 2020. Right: Subway turnstile being swabbed. Credit: Weill Cornell Medicine About 12,000 bacteria and viruses collected in a sampling from public transit systems and hospitals around the world from 2015 to 2017 had never before been identified, according to a study by the International MetaSUB Consortium, a global effort at tracking microbes that is led by Weill Cornell Medicine investigators. For the study, published on May 26, 2021, in the journal Cell, international investigators collected nearly 5,000 samples over a three-year period across 60 cities in 32 countries and six continents. The investigators analyzed the samples using a genomic sequencing technique called shotgun sequencing to detect the presence of various microbes, including bacteria, archaea (single-celled organisms that are distinct from bacteria), and viruses that use DNA as their genetic material. (Other types of viruses that use RNA as their genetic material, such as SARS-CoV-2, the virus that causes COVID-19, would not have been detected with the DNA analysis methods used in this pre-pandemic study.) This field of research has important implications for detecting outbreaks of both known and unknown infections and for studying the prevalence of antibiotic-resistant microbes in different urban environments. “Every time you sit down in the subway, you are likely commuting with an entirely new species,” said senior author Dr. Christopher Mason, co-director of the WorldQuant Initiative for Quantitative Prediction and a professor of physiology and biophysics at Weill Cornell Medicine. Mason is also co-founder and a paid consultant of Biotia and Onegevity Health, and a paid speaker for WorldQuant LLC. The current study led to the discovery of 10,928 viruses and 748 bacteria that are not present in any reference databases. Mason founded MetaSUB (short for Metagenomics and Metadesign of Subways and Urban Biomes) in 2015, along with Dr. Evan Afshin, then an undergraduate student at Macaulay Honors College at Queens College and now a clinical fellow in physiology and biophysics at Weill Cornell Medicine and a paid consultant for Onegevity Health. The newly released study was led by Mason, Dr. David Danko, a Weill Cornell Graduate School doctoral student in Mason’s lab during the study, and Daniela Bezdan, who was a research associate in computational biomedicine at Weill Cornell Medicine at that time. By collecting samples of microbes and analyzing their genes – collectively known as the microbiome – the researchers hope to learn more about the bacteria, viruses and other microorganisms that live among humans. For example, the research may help to identify the emergence of antibiotic-resistant strains. Predicting antibiotic resistance from genetic sequences alone is challenging, but the researchers were able to map some genes known to be linked to resistance, quantify their abundance and confirm the genetic markers’ ability to confer resistance. They found that some cities had more resistance genes than others, and that there might be city-specific signatures for some of these genes. Antimicrobial resistance remains a major global health challenge. “While further research is needed, this dataset demonstrates the value and potential for microbiome mapping and monitoring, and the insights it can provide physicians, scientists, and public health officials,” Afshin said. Moreover, learning about the small molecules and proteins made by microbes could also lead to the discovery of new antibiotics as well as other molecules that have the potential to be developed as drugs. Many antibiotics and drugs that are currently in use have been derived from microbial sources. Discoveries made about new microbial species could also lead to new laboratory tools and approaches, such as novel ways to use the molecular editing tool known as CRISPR. In this study, the researchers found 838,532 novel CRISPR arrays – snippets of viral DNA found inside bacteria – and 4.3 million new peptides (small proteins). Due to these sampling efforts, Mason said he can predict with about 90% accuracy where a person lives, just by sequencing the DNA on their shoes. Many factors were found to influence a city’s microbiome, including overall population and population density, elevation, proximity to the ocean and climate. The findings about these distinct signatures could enable future forensic studies. “A microbiome contains molecular echoes of the place where it was collected. A coastal sample may contain salt-loving microbes while a sample from a densely populated city may show striking biodiversity,” Danko said. Mason and Afshin began collecting and analyzing microbial samples in the New York City subway system in 2013. After they published their first findings, dubbed PathoMap, they were contacted by researchers from around the world who wanted to do similar studies for their own cities. The international interest inspired Mason’s lab to create MetaSUB and he recruited Daniela Bezdan as the research director. “We needed internationally accepted protocols, logistics and collaboration agreements with scientists, vendors, government offices and philanthropic foundations for potentially 100 cities in 20 countries,” Bezdan said. Today MetaSUB continues to grow and has expanded to collecting RNA and DNA samples from air, water and sewage, in addition to hard surfaces. This has led to a $5 million grant on wastewater sequencing and viral tracking across three states (Florida, New York and Wisconsin), and which is part of the Centers for Disease Control and Prevention’s new National Wastewater Surveillance System (NWSS). The group also oversees projects such as Global City Sampling Day (gCSD), held every year on June 21, and has done wide-ranging studies including a comprehensive microbial analysis of Rio de Janeiro before, during and after the 2016 Summer Olympics. Many of the samples analyzed in the current study were collected on Global City Sampling Day in 2016 and 2017. The New York City sampling effort was conducted with support from the Weill Cornell Medicine Clinical and Translational Science Center (CTSC), in collaboration with senior CTSC program manager Jeff Zhu. Mason and his colleagues are currently preparing for this year’s event. “When we started in 2015, the consortium consisted of 16 cities; six years later we have more than 100 cities. It’s great to have this group of curious, self-starting and enthusiastic co-investigators,” said Mason, who is also professor of computational genomics in computational biomedicine in the HRH Prince Alwaleed Bin Talal Bin Abdulaziz Al-Saud Institute for Computational Biomedicine at Weill Cornell Medicine. “Although samples are collected all over the world, much of the analysis is done right here in New York City at Weill Cornell Medicine,” Mason said. The analysis and assemblage of sequences also leveraged Bridges and Bridges-2, Extreme Science and Engineering Discovery Environment (XSEDE) supercomputers at the Pittsburgh Supercomputing Center. MetaSUB researchers in Switzerland (Drs. Andre Kahles and Gunnar Rätsch) used these assemblies and raw data to build a searchable, global DNA sequence portal (MetaGraph) that indexed all known genetic sequences (including MetaSUB data). The portal maps any known or newly discovered genetic elements to their location on Earth and can aid in the discovery of new microbial interactions and putative functions. DNA isolation from samples were largely performed with support from Zymo Research and Promega, and sequenced in collaboration with Dr. Shawn Levy at the HudsonAlpha Institute for Biotechnology, Dr. Klas Udekwu from Stockholm University and the New York Genome Center. Future and ongoing studies will look at RNA and DNA with long reads and spatial-imaging methods, as well as trace the metabolites from the global sites, and continue to update the planetary-scale genetic map. Reference: “A global metagenomic map of urban microbiomes and antimicrobial resistance” by David Danko, Daniela Bezdan, Evan E. Afshin, Sofia Ahsanuddin, Chandrima Bhattacharya, Daniel J. Butler, Kern Rei Chng, Daisy Donnellan, Jochen Hecht, Katelyn Jackson, Katerina Kuchin, Mikhail Karasikov, Abigail Lyons, Lauren Mak, Dmitry Meleshko, Harun Mustafa, Beth Mutai, Russell Y. Neches, Amanda Ng, Olga Nikolayeva, Tatyana Nikolayeva, Eileen Png, Krista A. Ryon, Jorge L. Sanchez, Heba Shaaban, Maria A. Sierra, Dominique Thomas, Ben Young, Omar O. Abudayyeh, Josue Alicea, Malay Bhattacharyya, Ran Blekhman, Eduardo Castro-Nallar, Ana M. Cañas, Aspassia D. Chatziefthimiou, Robert W. Crawford, Francesca De Filippis, Youping Deng, Christelle Desnues, Emmanuel Dias-Neto, Marius Dybwad, Eran Elhaik, Danilo Ercolini, Alina Frolova, Dennis Gankin, Jonathan S. Gootenberg, Alexandra B. Graf, David C. Green, Iman Hajirasouliha, Jaden J.A. Hastings, Mark Hernandez, Gregorio Iraola, Soojin Jang, Andre Kahles, Frank J. Kelly, Kaymisha Knights, Nikos C. Kyrpides, Pawel P. Labaj, Patrick K.H. Lee, Marcus H.Y. Leung, Per O. Ljungdahl, Gabriella Mason-Buck, Ken McGrath, Cem Meydan, Emmanuel F. Mongodin, Milton Ozorio Moraes, Niranjan Nagarajan, Marina Nieto-Caballero, Houtan Noushmehr, Manuela Oliveira, Stephan Ossowski, Olayinka O. Osuolale, Orhan Özcan, David Paez-Espino, Nicolás Rascovan, Hugues Richard, Gunnar Rätsch, Lynn M. Schriml, Torsten Semmler, Osman U. Sezerman, Leming Shi, Tieliu Shi, Rania Siam, Le Huu Song, Haruo Suzuki, Denise Syndercombe Court, Scott W. Tighe, Xinzhao Tong, Klas I. Udekwu, Juan A. Ugalde, Brandon Valentine, Dimitar I. Vassilev, Elena M. Vayndorf, Thirumalaisamy P. Velavan, Jun Wu, María M. Zambrano, Jifeng Zhu, Sibo Zhu, Christopher E. Mason and The International MetaSUB Consortium, 26 May 2021, Cell. DOI: 10.1016/j.cell.2021.05.002
DVDV1551RTWW78V
China ODM expert for comfort products 》functional, flexible, and built for scaleTaiwan insole ODM full-service provider factory 》your reliable OEM/ODM partner for long-term collaborationTaiwan insole ODM design and production 》manufacturing with a focus on sustainability and comfort